All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Fast Track Status to VLS-1488 for Platinum-Resistant High-Grade Serous Ovarian Cancer

October 3rd 2024

The KIF18A inhibitor VLS-1488 has received fast track designation from the FDA for platinum-resistant high-grade serous ovarian cancer.

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

October 2nd 2024

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma

October 2nd 2024

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

BPd Maintains QOL vs PVd, Supporting Its Use as a New SOC in R/R Myeloma

October 2nd 2024

No significant differences in patient-reported outcomes were observed with BPd vs PVd among patients with relapsed/refractory multiple myeloma.

Park and Leyfman Aim to Connect Oncology Community Through MedNews Week

October 2nd 2024

Chandler Park, MD, FACP, and Yan Leyfman, MD, discuss the goal of providing educational oncology content globally to oncologists via MedNews Week.

Bria-IMT Plus Immunotherapy Shows Early Promise in Breast Cancer Brain Metastasis

October 2nd 2024

Bria-IMT plus an immune checkpoint inhibitor completely resolved a breast cancer metastasis and shrunk an eye-bulging orbital lesion in 1 patient.

DCISionRT Biosignature Identifies Residual Recurrence Risk in HER2(3+) Breast Cancer

October 2nd 2024

DCISionRT identified patients with HER2-positive breast cancer at higher risk of residual disease following breast-conserving surgery plus radiotherapy.

Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer

October 2nd 2024

Research from Dana-Farber Cancer Institute clinicians showed that adding nivolumab to tivozanib did not improve survival for patients with advanced RCC.

Uncovering and Addressing Unmet Needs in Pediatric Cancer Care

October 2nd 2024

Saro H. Armenian, DO, MPH, discusses ongoing research that aims to enhance the quality of care for childhood cancer survivors.

HDP-101 Shows Early Efficacy and Manageable Safety Profile in Relapsed/Refractory Multiple Myeloma

October 2nd 2024

The BCMA-targeting ADC HDP-101 demonstrated early efficacy and manageable toxicity in relapsed/refractory multiple myeloma.

Trastuzumab/Pertuzumab May Be an Effective Chemo-Free Regimen in HR+/HER2+ Breast Cancer

October 2nd 2024

Dual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.

De-Escalated Neoadjuvant Treatment Does Not Compromise Survival Outcomes in HR+/HER2+ Early Breast Cancer

October 2nd 2024

Oleg Gluz, MD, highlights the feasibility of de-escalated neoadjuvant therapy plus trastuzumab and pertuzumab in patients with HR+/HER2+ breast cancer.

Neoantigen-Directed GRANITE Immunotherapy Improves PFS as Maintenance in MSS mCRC

October 2nd 2024

Maintenance with GRANITE plus fluoropyrimidine, bevacizumab, and checkpoint inhibitors improved PFS vs fluoropyrimidine plus bevacizumab alone in MSS mCRC.

HER2-Directed ADCs Spread Like Wildfire Across the Spectrum of Solid Malignancies

October 1st 2024

A panel of experts take stock of the current standing of HER2-directed ADCs in solid tumors, including breast, gynecologic, GI, lung, and GU cancers.

Cilta-Cel Shows Real-World Feasibility and Efficacy With Acceptable Safety in R/R Myeloma

October 1st 2024

Cilta-cel elicits high response rates with an acceptable toxicity profile in a real-world population of patients with relapsed/refractory multiple myeloma.

Allogeneic T-Cell Therapy Produces Efficacy at 10 Months in Stage IV Metastatic NSCLC

October 1st 2024

Treatment with Deltacel was safe and showed antitumor activity at 10 months in a patient with stage IV metastatic non–small cell lung cancer.

FDA Grants Priority Review to T-DXd in HR+, HER2-Low/-Ultralow Breast Cancer

October 1st 2024

The sBLA for trastuzumab deruxtecan in hormone receptor–positive, HER2-low or -ultralow breast cancer has been accepted for priority review by the FDA.

Roswell Park–Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer

October 1st 2024

Targeted Treatment Provides ORR and PFS Benefit in Pretreated Metastatic Solid Tumors

October 1st 2024

Targeted treatment as determined by mutational status was associated with ORR and PFS benefits in pretreated patients with metastatic solid tumors.

Cilta-Cel Prolongs OS in Lenalidomide-Refractory Multiple Myeloma

October 1st 2024

Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.